Scientists from Tel Aviv University have proven: a drug delivery system based on lipid nanoparticles
Chemoimmunotherapy combines two types of treatment andis considered the most advanced method for combating oncopathologies. While chemotherapy aims to kill cancer cells, immunotherapy stimulates the cells of the immune system to find and attack the remaining ones. However, many patients do not respond to chemoimmunotherapy because the treatment is not targeted enough. Professor Dan Pier and his team were the first in the world to prove the feasibility of a drug delivery system based on lipid nanoparticles. They release their payload only when they reach target cells - cancer cells for chemotherapy and immune cells for immunotherapy.
“In our system, one nanoparticle is capable ofwork in two different areas,” explains Prof. Pier. “It affects cancer cells that are resistant to chemotherapy and also activates immune cells. Thus, with one precisely targeted nanoparticle, we provide two different treatments.”
Scientists have already tested this system on twotypes of laboratory models - one with melanoma metastases, and the other for a local solid tumor. In both populations, biologists observed positive effects of the new delivery system.
Read more
Bacteria have appeared that synthesize the right drug directly in the human body
The new message for extraterrestrial civilizations is different from the rest: why is it dangerous
Look at a picture of a galaxy that looks like ours